Filsuvez^® (Birch Triterpenes) Topical Gel

Area of Science:

• Dermatology
• Wound Healing
• Pharmacology

Background:

• Epidermolysis bullosa (EB) is a rare genetic disorder characterized by fragile skin prone to blistering and wounds.
• Current treatments for EB focus on supportive care and wound management.
• Filsuvez (birch triterpenes) topical gel offers a novel therapeutic approach for EB wound healing.

Purpose of the Study:

• To evaluate the efficacy and safety of Filsuvez (birch triterpenes) topical gel in treating epidermolysis bullosa (EB) wounds.
• To compare the wound healing rates of birch triterpenes topical gel versus a vehicle gel in EB patients.

Main Methods:

• A randomized, double-blind, controlled, parallel-group, phase III trial (EASE, NCT03068780) involving 223 patients.
• Patients received either birch triterpenes topical gel or vehicle gel applied as a 1-mm layer to wounds every 4 days for 90 days.
• The primary endpoint was the first complete closure of the target EB wound by day 45.

Main Results:

• Complete wound closure by day 45 was achieved in 41.3% of patients treated with birch triterpenes topical gel, versus 28.9% in the vehicle gel group.
• Application site reactions were infrequent and comparable between the study gel (7.3%) and vehicle gel (6.1%) groups.
• Birch triterpenes topical gel demonstrated a statistically significant improvement in wound healing.

Conclusions:

• Filsuvez (birch triterpenes) topical gel is an effective treatment for promoting wound healing in patients with epidermolysis bullosa.
• The study supports the use of birch triterpenes topical gel as a therapeutic option for EB management.
• The recommended application is a 1-mm layer to the affected wound surface only.